Darren Pan, MD

Education
Fellowship, 06/2024 - Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai
Residency, 06/2020 - Internal Medicine, Icahn School of Medicine at Mount Sinai
MD, 06/2017 - Medicine, David Geffen School of Medicine at UCLA
Publications

  1. Dhakal B, Akhtar OS, Fandrei D, Jensen A, Banerjee R, Pan D, Richard S, Friend R, Rees MJ, Costello P, Vazquez Martinez MA, Pasvolsky O, Wagner CB, Davis JA, Castaneda Puglianini OA, Reshef R, Afrough A, Dima D, Bhutani M, Nadeem O, Parrondo RD, Freeman CL, Mikkilineni L, Raza S, Anderson LD, Kapoor P, Hosoya H, Chhabra S, Grajales-Cruz A, Gaballa MR, Midha S, Alsina M, Sborov DW, Patel KK, Lin Y, Ferreri CJ, Gagelmann N, Kumar AD, Hansen DK, Cowan AJ, Costa LJ, Merz M, Sidana S. Sequential Targeting in Multiple Myeloma: Talquetamab, a GPRC5D bispecific antibody, as a Bridge to BCMA CAR-T cell therapy. Blood 2025. PMID: 40749169


  2. Suresh A, Pan D, Lipof J, Kumar A, Arora S, Sayre P, Wolf J, Martin T, Chari A, Chung A. How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy? Immunotherapy 2025. PMID: 41104991


  3. Avigan ZM, Catlett J, Bodnar S, Pan D, Aleman A, Sheng T, Moshier E, Rossi AC, Richard S, Kaur G, Richter J, Sanchez LJ, Rodriguez C, Cho HJ, Hussein S, Salib C, Silverman LR, Jagannath S, Parekh S, Thibaud S. Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-cell Therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 2025. PMID: 40801897


  4. Pan D, Kumar A, Lipof JJ, Chung A, Wolf JL, Martin TG, Arora S, Sayre PH, Chari A. Emerging GPRC5D-Targeted therapies for multiple myeloma: a comprehensive review. Expert opinion on investigational drugs 2025. PMID: 40425184


  5. Pan D, Mouhieddine TH, Sheng T, Fu W, Moshier E, Richter J, Parekh S, Jagannath S, Rossi AC, Sanchez LJ, Thibaud S, Rodriguez C, Cho HJ, Richard S. Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in multiple myeloma. Bone marrow transplantation 2025. PMID: 40319194


  6. Avigan ZM, Bodnar S, Pan D, Catlett J, Richter J, Sanchez LJ, Rodriguez C, Rossi AC, Richard S, Jagannath S, Cho HJ, Parekh S, Thibaud S. Delayed neutrophil recovery following BCMA CAR-T therapy in Duffy-null myeloma does not impact severe infections or survival. Volume 9 of Issue 1. Blood advances 2025. PMID: 39383457


  7. Avigan ZM, Arinsburg S, Pan D, Mark T, Fausel C, Bubalo J, Milkovich G, Moshier E, Fu W, Chari A, Richter J. Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma. Bone marrow transplantation 2024. PMID: 39424960


  8. Pan D, Richter J. Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma. Volume 19 of Issue 6. Current hematologic malignancy reports 2024. PMID: 39145912


  9. Mejia Saldarriaga M, Pan D, Unkenholz C, Mouhieddine TH, Velez-Hernandez JE, Engles K, Fein JA, Monge J, Rosenbaum C, Pearse R, Jayabalan D, Gordillo C, Chan HT, Yamshon S, Thibaud S, Mapara M, Inghirami G, Lentzsch S, Reshef R, Rossi A, Parekh S, Jagannath S, Richard S, Niesvizky R, Bustoros M. Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma. Volume 8 of Issue 15. Blood advances 2024. PMID: 38776397


  10. Avigan ZM, Arinsburg S, Pan D, Mark T, Fausel C, Bubalo J, Milkovich G, Chari A, Richter J. Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma. Bone marrow transplantation 2024. PMID: 39085373


  11. Richter J, Pan D, Salinardi T, Rice MS. Real-world multiple myeloma front-line treatment and outcomes by transplant in the United States. Volume 4 of Issue 4. EJHaem 2023. PMID: 38024614


  12. Pan D, Richter J. Teclistamab for Multiple Myeloma: Clinical Insights and Practical Considerations for a First-in-Class Bispecific Antibody. Volume 15. Cancer management and research 2023. PMID: 37497430


  13. Mouhieddine TH, Van Oekelen O, Melnekoff DT, Li J, Ghodke-Puranik Y, Lancman G, Thibaud S, Pan D, Rajeeve S, Agte S, Aleman A, Sanchez L, Richard S, Rossi A, Richter J, Cho HJ, Rodriguez C, Lagana A, Moshier E, Chari A, Jagannath S, Parekh S. Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma. Blood advances 2023. PMID: 36018226


  14. Pan D, Mouhieddine TH, Upadhyay R, Casasanta N, Lee A, Zubizarreta N, Moshier E, Richter J. Outcomes with panobinostat in heavily pretreated multiple myeloma patients. Volume 50 of Issue 1-2. Seminars in oncology 2023. PMID: 37005144


  15. Pan D, Richter J. Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams. Volume 11. Frontiers in oncology 2022. PMID: 35127532


  16. Pan D, Kaufman JL, Htut M, Agrawal M, Mazumder A, Cornell RF, Zonder JA, Fay JW, Modiano MR, Moshier EL, Rush SA, Tunquist BJ, Chari A. Filanesib plus bortezomib and dexamethasone in relapsed/refractory t(11;14) and 1q21 gain multiple myeloma. Cancer medicine 2021. PMID: 34921527


  17. Pan D, Ip A, Zhan S, Wasserman I, Snyder DJ, Agathis AZ, Shamapant N, Yang JY, Pai A, Mazumdar M, Poor H. Pre-hospital antiplatelet medication use on COVID-19 disease severity. Volume 50 of Issue 5. Heart & lung : the journal of critical care 2021. PMID: 34090177


  18. Pan D, Coltoff A, Ozbek U, Lin JY, Afshar S, Galitzeck Z, Steinberg A. Evaluating Race and Time to Transplantation in Multiple Myeloma: The Mount Sinai Hospital Experience. Volume 21 of Issue 7. Clinical lymphoma, myeloma & leukemia 2021. PMID: 33757769


  19. Pan D, Rampal R, Mascarenhas J. Clinical developments in epigenetic-directed therapies in acute myeloid leukemia. Volume 4 of Issue 5. Blood advances 2020. PMID: 32150613


  20. Molina A, Winston DJ, Pan D, Schiller GJ. Response. Volume 24 of Issue 9. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2018. PMID: 29909155


  21. Molina A, Winston DJ, Pan D, Schiller GJ. Increased Incidence of Nocardial Infections in an Era of Atovaquone Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Volume 24 of Issue 8. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2018. PMID: 29555315